Grant Information
| Grant ID | RP250605 |
| Awarded On | May 21, 2025 |
| Title | Targeting the Epigenetic Reader TDRD1 in Prostate Cancer with Cyclic Peptide Inhibitors |
| Program | Academic Research |
| Award Mechanism | High Impact/High Risk |
| Institution/Organization | University of Houston |
| Principal Investigator/Program Director | Qin Feng |
| Cancer Sites | Prostate |
| Contracted Amount | $250000 |
| Lay Summary |
Prostate cancer is the most common non-skin cancer affecting men in the United States. The testis antigen TDRD1 (Tudor domain-containing 1) is found upregulated in about two-thirds of primary prostate cancers. TDRD1 is implicated in promoting tumor growth and resistance to antiandrogen therapies by interacting with methylated arginine residues through its Tudor domains. The proposed research applies phage display technology to identify TDRD1-specific cyclic peptide inhibitors, which provide enhanced stability and specificity compared to traditional small molecule inhibitors. The goal is to disrupt TDRD1's structured protein-protein interactions and consequently stop cancer progression. If su... |